What is Stoked Bio?
Stoked Bio operates at the vanguard of the biotechnology sector, specializing in the discovery and development of novel therapeutics for drug-resistant infections and oncology. By deploying a biology-first, AI-guided drug discovery approach, the company integrates high-fidelity experimental data with sophisticated machine learning algorithms. This methodology allows for the rapid identification and optimization of small-molecule drugs, effectively addressing clinical gaps where traditional treatment options remain limited or ineffective. By bridging the divide between computational modeling and laboratory validation, Stoked Bio is fundamentally re-engineering the drug development lifecycle to improve patient outcomes in high-acuity disease areas.
How much funding has Stoked Bio raised?
Stoked Bio has raised a total of $2.5M across 1 funding round:
Seed
$2.5M
Seed (2026): $2.5M, investors not publicly disclosed
Key Investors in Stoked Bio
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Stoked Bio?
With the infusion of $2.5M, Stoked Bio is poised to transition from its foundational research phase into a more aggressive clinical development cycle. The company's strategic roadmap focuses on leveraging its AI-driven platform to expand its portfolio of small-molecule candidates, specifically targeting resistant pathogens and complex cancer pathways. Future milestones will likely involve the expansion of laboratory capabilities and the potential initiation of preclinical trials. As the firm continues to refine its machine learning models, the focus will remain on reducing the time-to-market for life-saving therapeutics, thereby solidifying its position as a high-growth entity within the precision medicine landscape. Investors and industry stakeholders will be monitoring the company's ability to translate computational insights into tangible clinical success.
See full Stoked Bio company page
